PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Piperaquine Tetraphosphate→

Piperaquine Tetraphosphate PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
911061-10-4
Molecular formula
C29H44Cl2N6O16P4
Molecular weight
927.5 g/mol
Drug class
Bisquinoline antimalarialblood-schizonticidal agent
Mechanism of action
A bisquinoline antimalarial that interferes with haem detoxification in Plasmodium parasites, leading to accumulation of toxic haem species and parasite death. It is used clinically in combination with dihydroartemisinin; phosphate is a salt component, not a distinct active target.
Indications / reported uses
  • Treatment of uncomplicated Plasmodium falciparum malaria as part of the fixed-dose dihydroartemisinin–piperaquine combination, in accordance with current national malaria guidelines and resistance patterns

Sources: WHO prequalification — Eurartesim product information · EMA EPAR — Eurartesim · WHO Guidelines for malaria

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Piperaquine Tetraphosphate PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Piperaquine Tetraphosphate Permitted Daily Exposure (PDE) report (the Piperaquine Tetraphosphate PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Piperaquine Tetraphosphate Occupational Exposure Limit (OEL) report (the Piperaquine Tetraphosphate OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.